ZEVRA THERAPEUTICS, INC. - 10-Q Filing

Zevra Therapeutics reports Q3 2026 financial results including updated segment operating costs and derivative liability fair value disclosures.

SEC EDGAR ·

Tickers: $KMPH

Read the full article at SEC EDGAR

More Regulatory news